myNEO Therapeutics is a distinguished biopharmaceutical powerhouse, dedicated to pioneer breakthrough immunotherapies to fight cancer. myNEO Therapeutics is leveraging its ImmunoEngine discovery platform to tap into novel promising tumor targets found in the dark genome – named camyotopes™ – which have the potential to unlock immunotherapy for large patient populations who currently do not respond.
In parallel, the service angle of myNEO Therapeutics, myNEO Intelligence, assists biopharma companies in transforming their decision-making process from trial & error to data-driven decisions using an AI-powered platform. Deriving insights from its expansive library of clinical and molecular data, myNEO Intelligence maps the molecular profiling of cancer patients at an individual level and then correlates the different data points to make data-driven decisions across the drug development life cycle. myNEO Intelligence can identify novel targets and biomarkers, prioritize drug candidates and indications, stratify patient populations and predict treatment response.
Gitta studied Biochemistry and Biotechnology at the University of Antwerp and performed her Master thesis about epigenetic cancer biomarkers at the lab for ‘Translational Research and Microfluidics’ at Paris Descartes University. Thereafter, she successfully pursued an FWO-funded PhD in oncogenetics at the Center for Oncological Research and the Center of Medical Genetics in Antwerp. During her PhD research about (epi)genetic alterations as (liquid) cancer biomarkers she became very interested in bioinformatics, which resulted in an advanced bachelor of Bioinformatics at the Howest.
In 2022, she started as a Data Scientist at myNEO Therapeutics, where she contributes towards improving and expanding the neoantigen discovery pipeline, and a variety of internal and external projects.